Literature DB >> 11812907

Anaemia management in chronic kidney disease patients: an overview of current clinical practice.

Fernando Valderrábano1.   

Abstract

This paper describes three recent, related surveys of anaemia management practice in patients with chronic kidney disease, with particular emphasis on initiation of epoetin therapy. It also compares current practice with the European Best Practice Guidelines (EBPG) for anaemia management. The European Survey of Anaemia Management (ESAM) was a 6 month, longitudinal prospective survey of anaemia management in dialysis patients. Although most survey data concerned patients already on dialysis, some retrospective data concerned initiation of dialysis and epoetin therapy. These findings led to the Predialysis Survey of Anaemia Management (PRESAM), a cross-sectional, retrospective survey of patients beginning dialysis, focusing on referral to renal centres and anaemia management in the year preceding dialysis. The Early Renal Insufficiency Referral Survey (ERIRS) is a further cross-sectional survey currently in progress, investigating referral practices during pre-dialysis care. Collectively, these three surveys provide a wealth of data about pre-dialysis anaemia management. ESAM included data from 14527 patients, PRESAM from 4333 patients, and data from 724 patients enrolled in ERIRS have been analysed. The evidence indicates that, at the time of referral to a renal centre, most patients have haemoglobin concentrations well below the levels recommended by the EBPG. Haemoglobin concentrations are lowest in patients referred within the month prior to the initiation of dialysis. Most patients do not start epoetin treatment until dialysis is initiated, despite having haemoglobin concentrations below the level recommended by the EBPG for the initiation of epoetin. Patients who are referred earlier (i.e. those under the care of the renal centre nephrologist for more than a month before the initiation of dialysis) tend to have higher haemoglobin concentrations and are more likely to be receiving epoetin therapy. Such patients are in the minority, however, indicating that pre-dialysis anaemia management practices continue to fall short of the recommendations of the EBPG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812907     DOI: 10.1093/ndt/17.suppl_1.13

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Anemia and cardiovascular disease in diabetic nephropathy.

Authors:  Samy I McFarlane; Moro O Salifu; John Makaryus; James R Sowers
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

2.  Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients.

Authors:  Jean-Christophe Luthi; W Dana Flanders; Michel Burnier; Bernard Burnand; William M McClellan
Journal:  BMC Nephrol       Date:  2006-03-06       Impact factor: 2.388

3.  Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.

Authors:  Hitesh M Soni; Amit M Vekaria; Akshyaya C Rath; Sateesh Belemkar; Mukul R Jain
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

4.  Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial.

Authors:  Abbas Norouzi Javidan; Heshmatollah Shahbazian; Amirhossein Emami; Mir Saeed Yekaninejad; Hassan Emami-Razavi; Masoumeh Farhadkhani; Ahmad Ahmadzadeh; Fazel Gorjipour
Journal:  Hematol Rep       Date:  2014-09-10

5.  Association between diabetes mellitus and anemia among Korean adults according to sex: a cross-sectional analysis of data from the Korea National Health and Nutrition Examination Survey (2010-2016).

Authors:  Mihye Kim; Sook-Hyun Lee; Kyoung Sun Park; Eun-Jung Kim; Sujung Yeo; In-Hyuk Ha
Journal:  BMC Endocr Disord       Date:  2021-10-21       Impact factor: 2.763

6.  A case-control study of prevalence of anemia among patients with type 2 diabetes.

Authors:  Samuel Antwi-Bafour; Samuel Hammond; Jonathan Kofi Adjei; Ransford Kyeremeh; Alexander Martin-Odoom; Ivy Ekem
Journal:  J Med Case Rep       Date:  2016-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.